Press Release July 28, 2022

Larkspur Health Acquisition Corp. to Merge with ZyVersa Therapeutics

Alston & Bird client Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, has announced a definitive agreement to merge with ZyVersa Therapeutics Inc., a clinical stage specialty biopharmaceutical company.
The $108.92 million combination is expected to close during the fourth quarter of 2022, subject to approval by shareholders of Larkspur and shareholders of ZyVersa.
Representing Larkspur is an Alston & Bird team led by partners Matt Mamak and Stuart Rogers, senior associate Robyn Downing, and associates Misbah Mohiuddin and Siena Cornacchini (Corporate & Business Transactions) and associate Trenton Hafley (Litigation & Trial Practice).
Media Contact
Alex Wolfe
Communications Director
Phone: 212.210.9442

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.